A Phase 1b clinical trial evaluating Serina Therapeutics’s SER-252 (POZ-apomorphine) in people with advanced Parkinson’s disease has enrolled its first patient, the company announced. The global registrational trial is evaluating the treatment’s safety, tolerability, pharmacokinetics, and preliminary efficacy. The first group of participants is being enrolled in Australia, where…
